Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation
Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
Within the US 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.' is sponsor.
Inclusion Criteria:
Exclusion Criteria:
Imba, Chiba 270-1694, Japan
Chikushi-gun, Fukuoka 811-1244, Japan
Mebashi, Gunma 371-0014, Japan
Higashiibaraki, Ibaraki 311-3193, Japan
Nangoku, Kochi 783-8509, Japan
Kasukage, Saitama 344-0035, Japan
Edogawa-ku, Tokyo 133-0052, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Itabashi-ku, Tokyo 175-0082, Japan
Meguro-ku, Tokyo 153-8515, Japan
Shibuya-ku, Tokyo 150-0013, Japan
Shinagawa-ku, Tokyo 141-0001, Japan
Shinjuku-ku, Tokyo 162-8655, Japan
Higashikawada, Yamagata 999-7782, Japan